DNAJC14

Across TCGA pan-cancer cohorts, DNAJC14 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DNAJC14 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DNAJC14 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DNAJC14 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where DNAJC14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.852	1.000	<.001	36	view →
HNSC	OS	Tertile	III,IV	0.596	0.872	.001	31	view →
LSCC	DFS	Tertile	All	0.990	0.924	.010	8	view →
PDAC	DFS	Quartile	All	0.673	0.950	.004	8	view →
GBM	DFS	Quartile	All	0.824	0.336	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DNAJC14–LUAD (DFS)

Open the LUAD breakdown →